Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma.

Next Previous
Search
Trial Profile

Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Sep 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 06 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 13 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top